AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Immuron Ltd Board/Management Information 2007

Jul 19, 2007

35121_rns_2007-07-19_55e8cdda-7a0e-4c3c-8a5e-4be566b46706.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [67 x 77] intentionally omitted <==

Company Announcement

Change of Chairman

Friday 20 July 2007

Anadis Ltd (ASX:ANX) announced today the retirement of Non-Executive Director and Chairman of the Board, Mr. Philip Molyneux. The Board wishes to record its sincere appreciation for the contribution of Mr. Molyneux in his role as Chairman over the past 10 years. During that time the Company has set down some very solid foundations for a sustainable business derived from innovative Australian medical research.

The Board is pleased to announce that Mr. Roman Zwolenski has accepted to take the position of Chairman of the Board. Mr. Zwolenski’s experience in the biotechnology industry spans more than 30 years and includes leadership positions including Vice Director of Roche Diagnostics based in Switzerland, followed by two appointments as CEO of globally focused publicly listed (ASX) biotech companies. He has been a Non-Executive Director of Anadis for almost 5 years. Most recently he served Anadis for several months in the role of an Executive Director to assist in transitioning the business into the next phase of its development. The transition process is moving swiftly and in April 2007 the Company appointed a new CEO, Dr Zeil Rosenberg, based in the USA.

The Board is confident that the combination of Mr. Zwolenski as Non-Executive Chairman and Dr Rosenberg the new CEO gives Anadis strong leadership for the Company’s next phase of growth.

For further information contact:

Mr. Roman Zwolenski - Chairman

Email: [email protected] Tel: +61 3 9358 6388